AbbVie Inc., US00287Y1091

AbbVie stock ends the day higher at USD 265.51

Published on 09/22/2026 at 23:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 22, 2026, AbbVie stock gained 0.39 percent to USD 265.51 on the NYSE, with a session range of USD 264.12 to USD 265.63. The company also announced a European approval for RINVOQ.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung
AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie stock closed at USD 265.51 on the NYSE on September 22, 2026, up 0.39 percent from the prior close of USD 264.48. The shares opened at USD 265.06 and traded between USD 264.12 and USD 265.63 during the session.

September 22, 2026 in numbers

AbbVie Inc. (ISIN US00287Y1091, NYSE: ABBV) finished USD 1.03 above the previous close. Trading volume was 892,624 shares, compared with an average volume of 6,538,061 shares, while the 52-week range extended from USD 190.75 to USD 267.47. The close was USD 1.96 below the 52-week high.

The company announced European Commission approval of RINVOQ for children with active polyarticular juvenile idiopathic arthritis on September 22, 2026. StockTitan also carried AbbVie news about the U.S. launch of AA Signature: SKIN360, announced at 8:00 a.m. ET.

Events after the bell today

AbbVie stock had an estimated next earnings date of October 30, 2026, according to MarketBeat. The next scheduled dividend ex-date is October 15, 2026, with a payment date of November 16, 2026.

Disclaimer...

en | US00287Y1091 | ABBVIE INC. | boerse | 70160013 | bgmi